Longitudinal clinical response to Janus kinase inhibitors in systemic sclerosis: a real-life multicentric study across multiple clinical domains - Takeaways - MDSpire

Longitudinal clinical response to Janus kinase inhibitors in systemic sclerosis: a real-life multicentric study across multiple clinical domains

  • By

  • Stefano Di Donato

  • Juan José Alegre-Sancho

  • Anastas Batalov

  • Zguro Batalov

  • Silvia Bellando-Randone

  • Carmela Coccia

  • Marco De Pinto

  • Dilia Giuggioli

  • Michael Hughes

  • May 30, 2026

  • 0 min

Share

  • 1

    Systemic sclerosis (SSc) is characterized by immune dysregulation, vascular dysfunction, and progressive fibrosis, with an inflammatory component in some patients.

  • 2

    Janus kinase inhibitors (JAKi’s) target inflammatory pathways and may inhibit cytokine signals involved in SSc, potentially affecting both inflammation and fibrosis.

  • 3

    The study aimed to report real-world data on the safety and effectiveness of JAKi treatment in patients with SSc across multiple clinical domains.

  • 4

    Inclusion criteria for the study included a diagnosis of SSc, age ≥ 18 years, exposure to a JAK inhibitor, and availability of clinical data.

  • 5

    Outcomes assessed included drug survival, clinical effectiveness, and glucocorticoid sparing effect over time in patients treated with JAK inhibitors.

Original Source(s)

Longitudinal clinical response to Janus kinase inhibitors in systemic sclerosis: a real-life multicentric study across multiple clinical domains

  • by Stefano Di Donato, Juan José Alegre-Sancho, Anastas Batalov, Zguro Batalov, Silvia Bellando-Randone, Carmela Coccia, Marco De Pinto, Dilia Giuggioli, Michael Hughes

  • May 30, 2026

Related Content

EULAR Updates Behçet’s Syndrome Recommendations

EULAR releases updated recommendations supporting earlier biologic use in patients with eye, vascular, and nervous system involvement

The Relationship Between Microbiota and Systemic Lupus Erythematosus: Insights into Mechanisms, Diagnostic Approaches, and Treatment Innovations

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.